Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Almada

96 clinical trials in Almada, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Almada at a glance
96
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

96 trials in Almada

Open in trial search
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Almada

What the registry says about research in the country

01 Respiratory and Pulmonary Research

Clinical trials focusing on pulmonary arterial hypertension and chronic obstructive pulmonary disease, evaluating novel treatments including ralinepag and itepekimab for long-term management of these conditions.

  • COPD Treatment Development
  • Pulmonary Hypertension Therapy
  • Long-term Safety Studies
02 Autoimmune and Inflammatory Conditions

Research investigating treatments for systemic lupus erythematosus, rheumatoid arthritis, and other inflammatory conditions, with studies on medications like upadacitinib and remibrutinib.

  • Lupus Management
  • Arthritis Treatments
  • Inflammatory Disease Therapies
03 Neurological Disorders

Studies examining treatments for multiple sclerosis, migraine prevention, and neurological conditions, testing medications such as ocrelizumab and atogepant.

  • MS Treatment Evaluation
  • Migraine Prevention
  • Neurological Disease Management
04 Cardiovascular Research

Investigations into hypertrophic cardiomyopathy and stroke prevention, studying treatments like mavacamten and asundexian for improved cardiac outcomes.

  • Heart Disease Management
  • Stroke Prevention
  • Cardiac Structure Studies
05 Oncology Research

Advanced studies in lung cancer, colorectal cancer, and head and neck cancers, evaluating novel immunotherapy combinations and targeted treatments.

  • Cancer Immunotherapy
  • Targeted Cancer Treatments
  • Metastatic Disease Management
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).